CD8A and cancer: Pegilodecakin (PEGylated IL-10; PEG-IL-10; AM0010) is an IL-10-based antineoplastic agent that stimulates systemic immune responses and enhances intratumoral CD8+ T lymphocyte invigoration in cancer patients, according to early preclinical studies (Figure 5C) (171).